title: Self-assembled nanoparticles of hyaluronic acid/poly(DL-lactide-co-glycolide) block copolymer.
abstract: We synthesized block copolymer composed of hyaluronic acid (HA) and poly(DL-lactide-co-glycolide) (PLGA) (HAbLG) for antitumor targeting. (1)H NMR was employed to confirm synthesis of block copolymer. At (1)H NMR study, HabLG nanoparticles showed HA intrinsic peaks only at D(2)O, indicating that they contained HA as a hydrophilic outer-shell and PLGA as a inner-core. Anti-tumor activity was studied using CD44-overexpressing HCT-116 human colon carcinoma cells. Addition of doxorubicin (DOX)-incorporated nanoparticles to tumor cells resulted in the expression of a strong red fluorescence color while they expressed very weak fluorescence when CD44 receptor was blocked with free HA. Flow cytometry data also showed similar results, indicating that the fluorescence intensity of tumor cells treated with nanoparticles was significantly decreased when CD44 receptor was blocked. These results indicate that HAbLG nanoparticles were able to target CD44-overexpressing tumor cells via receptor-mediated endocytosis.
authors: National Research and Development Center for Hepatibiliary Disease, Pusan National University YangSan Hospital, Yangsan, Gyeongnam, Republic of Korea.
authors: Young-Il
authors: YI
authors: Jeong
authors: Do Hyung
authors: DH
authors: Kim
authors: Chung-Wook
authors: CW
authors: Chung
authors: Jin Ju
authors: JJ
authors: Yoo
authors: Kyung Ha
authors: KH
authors: Choi
authors: Cy Hyun
authors: CH
authors: Kim
authors: Seung Hee
authors: SH
authors: Ha
authors: Dae Hwan
authors: DH
authors: Kang
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D001667:Binding, Competitive; D002277:Carcinoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D003692:Delayed-Action Preparations / Q000737:chemistry* / Q000378:metabolism; D017666:Deuterium Oxide / Q000032:analysis / Q000378:metabolism; D004317:Doxorubicin / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D004337:Drug Carriers / Q000737:chemistry* / Q000378:metabolism; D004705:Endocytosis; D005434:Flow Cytometry; D005453:Fluorescence; D006801:Humans; D018960:Hyaluronan Receptors / Q000276:immunology / Q000378:metabolism; D006820:Hyaluronic Acid / Q000737:chemistry*; D057927:Hydrophobic and Hydrophilic Interactions; D019344:Lactic Acid / Q000737:chemistry*; D009682:Magnetic Resonance Spectroscopy; D058990:Molecular Targeted Therapy / Q000379:methods*; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D018960:Hyaluronan Receptors; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D004317:Doxorubicin; D006820:Hyaluronic Acid; D017666:Deuterium Oxide